← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Ulcerative Colitis

Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 292
Awards & highlights

Summary

This trial is testing the safety and effectiveness of Deucravacitinib in patients with moderate to severe Crohn's disease or Ulcerative Colitis who were part of an earlier study. The medication aims to reduce inflammation and improve symptoms.

Eligible Conditions
  • Ulcerative Colitis
  • Crohn's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 292
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 292 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of AEs leading to study discontinuation
Number of adverse events (AEs)
Number of clinically significant abnormalities in clinical laboratory results: Clinical Chemistry test
+10 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Long-Term Extension Rollover Study: DeucravacitinibExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~160

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,652 Previous Clinical Trials
4,130,682 Total Patients Enrolled
13 Trials studying Ulcerative Colitis
8,585 Patients Enrolled for Ulcerative Colitis

Media Library

Deucravacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04877990 — Phase 2
Ulcerative Colitis Research Study Groups: Long-Term Extension Rollover Study: Deucravacitinib
Ulcerative Colitis Clinical Trial 2023: Deucravacitinib Highlights & Side Effects. Trial Name: NCT04877990 — Phase 2
Deucravacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04877990 — Phase 2
~15 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top